Back to Search
Start Over
Biologicals for the prevention of anaphylaxis
- Source :
- Current Opinion in Allergy & Clinical Immunology. 21:303-308
- Publication Year :
- 2021
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2021.
-
Abstract
- PURPOSE OF REVIEW To review the use of biological agents (BA) in the treatment of anaphylaxis in the view of the new knowledge in the field to support the quality of care and prevention. RECENT FINDINGS Some BA, as a single medication or as combined therapy to food or venom immunotherapy, are effectively able to reduce most of the severe anaphylactic reactions. SUMMARY Anaphylaxis is a recognized clinical emergency, which requires prompt identification and treatment. Several biologic therapies and new devices are emerging as a potential preventive treatment for anaphylaxis. However, adrenaline (epinephrine) is still the first-line treatment for any type of anaphylaxis. Biological drugs, such as omalizumab, whereas not US Food and Drug Administration (FDA) nor European Medicines Agency (EMA) approved for anaphylaxis, have been used as therapeutic adjuvants in the preventive treatment of anaphylaxis, but cost-effectiveness should be considered individually.
- Subjects :
- Biological Products
medicine.medical_specialty
Epinephrine
business.industry
Immunology
Biologic therapies
Anaphylactic reactions
Omalizumab
Allergens
medicine.disease
Food and drug administration
Biological drugs
Desensitization, Immunologic
Humans
Immunology and Allergy
Medicine
Combined therapy
business
Intensive care medicine
Anaphylaxis
medicine.drug
Subjects
Details
- ISSN :
- 14736322 and 15284050
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Current Opinion in Allergy & Clinical Immunology
- Accession number :
- edsair.doi.dedup.....72f74b8a164fe22a126cc155f1639f7f